Table 1 Clinical and laboratory characteristics of secondary dengue patients with DHF and DF recruited for the study
From: Role of NS1 antibodies in the pathogenesis of acute secondary dengue infection
Clinical findings | DHF (n = 33) | DF (n = 22) |
|---|---|---|
Vomiting | 14 (42.42%) | 5 (22.72%) |
Abdominal pain | 21 (63.63%) | 5 (22.72%) |
Hepatomegaly | 28 (84.84%) | 0 |
Bleeding manifestations | 1 (03.03%) | 3 (13.63%) |
Pleural effusion | 18 (54.54%) | 0 |
Ascites | 33 (100.0%) | 0 |
Lowest platelet count | Â | Â |
  <20,000 cells/mm3 | 23 (69.69%) | 2 (9.09%) |
  20,000–50,000 | 10 (30.30%) | 9 (40.90%) |
  50,000–100,000 | 0 | 8 (36.36%) |
  >100,000 | 0 | 3 (13.63%) |
Lowest lymphocyte count | Â | Â |
  < 750 | 21 (63.63%) | 9 (40.90%) |
  750–1500 | 10 (30.30%) | 13 (59.09%) |
  >1500 | 2 (6.06%) | 0 |
Infecting serotype | ||
  DENV1 | 10 (30.30%) | 10 (45.45%) |
  DENV2 | 23 (69.69%) | 12 (54.54%) |
